Single dose c2n-8e12    (DrugBank: -)

1 disease
IDDisease name (Link within this page)Number of trials
5Progressive supranuclear palsy1

5. Progressive supranuclear palsy    [ 82 clinical trials,   107 drugs,   (DrugBank: 36 drugs),   60 drug target genes,   90 drug target pathways]
Searched query = "Progressive supranuclear palsy", "PSP"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
1 / 82 trial found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT02494024
(ClinicalTrials.gov)
July 201530/6/2015Safety, Tolerability, and Pharmacokinetics of C2N-8E12 in Subjects With Progressive Supranuclear PalsyA Double-Blind, Placebo Controlled, Single Ascending Dose Study to Assess the Safety, Tolerability, and Pharmacokinetics of C2N-8E12 in Subjects With Progressive Supranuclear PalsyProgressive Supranuclear PalsyDrug: Single dose C2N-8E12;Drug: Single dose placeboC2N DiagnosticsNULLCompleted50 Years85 YearsAll32Phase 1United States